newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

  • Immix Biopharma (NASDAQ: IMMX) will present NXC-201 abstract data at the ASH 67th Annual Meeting in Orlando, Florida, from December 6-9, 2025.
  • AL amyloidosis involves misfolded amyloid proteins causing heart, kidney, & liver failure, with U.S. relapsed/refractory prevalence estimated at 37,270 patients in 2025.
  • The U.S. relapsed/refractory AL amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion in 2025.
  • Immix's lead candidate NXC-201 is a sterically-optimized BCMA-targeted CAR-T therapy featuring a "digital filter" to prevent non-specific activation.
  • NXC-201 is evaluated in the registrational NEXICART-2 study, which met its primary endpoint at interim results presented at ASCO 2025.
  • NXC-201 holds RMAT status from the FDA, plus Orphan Drug Designations from the FDA & EMA.
  • Forward-looking statements include risks regarding clinical trial consistency, funding availability, regulatory approval, & the potential for trial failure.